Kidney Cancer Articles

Molecular Subtypes Correlate With Outcomes in RCC
Molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with significant differences seen in overall survival and disease-free survival between groupings.
Rana R. McKay, MD, discusses the evolving management of patients with advanced RCC, specifically the future of combinations of with immunotherapy regimens.
McDermott Shares Insight on Immunotherapy in RCC
David F. McDermott, MD, discusses the successes with immunotherapy in renal cell carcinoma and gave his insight on the future treatment of these patients.
FDA Grants Pembrolizumab/Lenvatinib Breakthrough Designation for RCC
The FDA has granted the combination of the PD-1 inhibitor pembrolizumab and the VEGF/FGF inhibitor lenvatinib a breakthrough therapy designation for the treatment of patients with advanced and/or metastatic renal cell carcinoma.
FDA Grants Frontline Avelumab/Axitinib Breakthrough Designation for RCC
The FDA has granted the PD-L1 inhibitor avelumab a breakthrough therapy designation for use in combination with the VEGF inhibitor axitinib in treatment-naïve patients with advanced renal cell carcinoma.
 
FDA Approves Frontline Cabozantinib for Advanced RCC
The FDA has approved cabozantinib for previously untreated patients with advanced renal cell carcinoma.
Pembrolizumab Investigated as Adjuvant RCC Therapy
Tian Zhang, MD, discusses KEYNOTE-564, as well as the progress that immunotherapy has made in the treatment paradigm of patients with RCC.
FDA Grants Nivolumab/Ipilimumab Priority Review for RCC
The FDA has granted a priority review to a sBLA for use of the combination of nivolumab and ipilimumab as a frontline treatment for intermediate- and poor-risk patients with advanced RCC.
Atezolizumab Plus Bevacizumab Meets Primary Endpoint for PFS in Advanced or Metastatic mRCC
In top-line results from the phase III IMmotion151 trial, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) was associated with a statistically significant reduction in the risk for death or progression in patients with PD-L1
Immunotherapy Combinations Poised to Shift Standard of Care in RCC
Hans Hammers, MD, PhD, discusses the game-changing combination of nivolumab and ipilimumab and highlighted other combinations that have potential in the treatment of patients with renal cell carcinoma.
Publication Bottom Border
Border Publication
x